From Nasdaq: 2024-04-05 22:02:25

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for treating HER2-positive solid tumors in adult patients who have exhausted other treatment options. The approval is based on response rate and duration of response, with continued approval dependent on further clinical trials. Enhertu is a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and is a joint effort with AstraZeneca. This news brings hope to patients with limited treatment options for this type of cancer. For more health news, visit rttnews.com.



Read more at Nasdaq: FDA Approves AstraZeneca And Daiichi Sankyo’s Enhertu For Solid Tumors Treatment